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BACKGROUND: Body mass index (BMI) has been suggested to be 
causally related to cardiovascular health in mid-to-late life, but this has 
not been explored systematically at younger ages—nor with detailed 
cardiovascular phenotyping. Recall-by-Genotype (RbG) is an approach that 
enables the collection of precise phenotypic measures in smaller studies, 
while maintaining statistical power and ability for causal inference.
METHODS: In this study, we used a combination of conventional 
multivariable regression analysis, Mendelian randomization (MR), and 
subsample RbG methodologies to estimate the causal effect of BMI on 
gross-level and detailed cardiovascular health in healthy participants from 
the Avon Longitudinal Study of Parents and Children at age 17 years 
(N=1420–3108 for different outcomes) and an independent sample from 
the same cohort (for RbG) study at age 21 years (N=386–418).
RESULTS: In both MR and RbG analyses, results suggested that higher 
BMI causes higher blood pressure and left ventricular mass index in young 
adults (eg, difference in left ventricular mass index per 1 kg/m2 using 
MR: 1.07 g/m2.7; 95% CI, 0.62–1.52; P=3.87×10-06 and per 3.58 kg/m2 
using RbG: 1.65 g/m2.7; 95% CI, 0.83–2.47; P=0.0001). Additionally, RbG 
results suggested a causal role of higher BMI on higher stroke volume 
(difference per 3.58 kg/m2: 1.49 mL/m2.04; 95% CI, 0.62–2.35; P=0.001) 
and cardiac output (difference per 3.58 kg/m2: 0.11 L·min-1·m-1.83; 95% 
CI, 0.03–0.19; P=0.01) but no strong evidence for a causal role on 
systemic vascular resistance or total arterial compliance. Neither analysis 
supported a causal role of higher BMI on heart rate.
CONCLUSIONS: Complementary MR and RbG causal methodologies, 
together with a range of sensitivity analyses, suggest that higher BMI 
is likely to cause worse cardiovascular health, specifically higher blood 
pressure and left ventricular mass index, even in youth. Higher BMI also 
resulted in increased cardiac output in the RbG study, which appeared 
to be solely driven by stroke volume, as neither MR nor RbG analyses 
suggested a causal effect of BMI on heart rate. These consistent results 
support efforts to reduce BMI from a young age to prevent later adverse 
cardiovascular health and illustrate the potential for phenotypic resolution 
with maintained analytic power using RbG.
© 2018 The Authors. Circulation is 
published on behalf of the American 
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Kluwer Health, Inc. This is an open 
access article under the terms of the 
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Higher body mass index (BMI) in adulthood is like-ly to cause numerous adverse cardiovascular risk factors and disease outcomes.1–5 These relation-
ships may reflect long-term exposure to high adipos-
ity and other comorbidities, which then result in ad-
verse structural and functional cardiovascular changes 
that are different from adaptations encountered earlier 
in the disease’s evolution. Indeed, recent results from 
adult bariatric surgery patients provide supportive evi-
dence for a causal role of greater adiposity on risk of 
major cardiovascular events.3 However, the nature of 
these relationships has been assessed predominantly 
in populations of adults, and no large studies have ex-
plicitly assessed the causal impact of BMI on detailed 
cardiovascular phenotypes in early life, where risk may 
emerge. Observational studies have reported associa-
tions between higher BMI and the presence of various 
subclinical markers of cardiovascular disease6–8; how-
ever, these can struggle to make a distinction between 
correlation and causation due to issues such as con-
founding or reverse causation.
One method for establishing evidence for causality 
in associations between an exposure and outcome of 
interest is Mendelian randomization (MR). This tech-
nique uses genetic variants as instrumental variables (or 
proxy measures) in otherwise observational epidemio-
logical studies.9 The application of MR methodology 
has thus far provided evidence to support a causal role 
of higher BMI on increasing the risk of various cardio-
metabolic diseases, predominantly in large populations 
of adults.2,4,5 However, because of the technique’s re-
quirement for large sample sizes to provide adequate 
statistical power, MR studies traditionally use routine-
ly collected clinical measures or data generated from 
high-throughput technologies. To examine this poten-
tially serious problem in the case of BMI and cardiovas-
cular health of the young, detailed and precise subclini-
cal measures of early structural and functional vascular 
adaptations are needed to help elucidate pathophysiol-
ogy and disease etiology. However, these are not com-
monly carried out in large population studies, as they 
are expensive, are time-consuming, and require highly 
skilled operators. Therefore, such measures are limited 
in their availability for MR analyses, particularly within 
healthy young population samples.
Recall-by-Genotype (RbG) studies are an innovative 
extension of MR methodology, designed to improve 
study efficiency, enable genotype-driven deep-pheno-
typing, and improve causal inferences.10 This is achieved 
through the recall of participants based on already 
available genotypes that are known to be reliably corre-
lated with exposures of interest (eg, BMI). Like MR and 
thus randomized, controlled trials, the random alloca-
tion of alleles at conception produces genotype groups 
that are theoretically independent of confounders and 
those that escape the problems of reverse causation. 
By recalling specific subgroups of a total sample with 
known exposure, the technique enables the efficient 
collection of precise phenotypic data that may be oth-
erwise impractical at the scale necessary to achieve sta-
tistical power in MR analyses.10
Using data from ALSPAC (Avon Longitudinal Study 
of Parents and Children), we aimed to use both whole-
sample MR and subsample RbG, alongside convention-
al multivariable regression analyses, to test the hypoth-
esis that BMI causally influences variations in multiple 
clinically relevant measures of cardiovascular structure 
and function in adolescence and early adulthood.
METHODS
Cohort Description
ALSPAC is a prospective birth cohort study investigating 
factors that influence normal childhood development and 
Clinical Perspective
What Is New?
• The relationship between body mass index (BMI) 
and detailed cardiovascular measures has not been 
explored in young adults.
• We triangulated findings from 3 different analytic 
approaches with differing key sources of bias: con-
ventional multivariable regression, Mendelian ran-
domization, and a Recall-by-Genotype study design.
• The last is novel and exploits the random assort-
ment of alleles through meiotic cell division at 
conception to inform genetically based recall and 
allows for the collection of extremely precise car-
diovascular phenotypes that would otherwise be 
impractical at scale.
• This study illustrated the potential for pheno-
typic resolution with maintained analytic power 
and ability to draw causal inferences using 
Recall-by-Genotype.
What Are the Clinical Implications?
• Results suggested that higher BMI causes higher 
blood pressure (systolic and diastolic blood pres-
sure, pulse pressure, and mean arterial pressure) 
and left ventricular mass index, the last suggesting 
adverse effects on cardiac structure, even in young 
adults.
• Recall-by-Genotype analyses also suggested 
that higher BMI increased cardiac output, which 
appeared to be solely driven by stroke volume, as 
neither Mendelian randomization nor Recall-by-
Genotype analyses suggested a causal effect of 
BMI on heart rate.
• Our results support efforts to reduce BMI from a 
young age to prevent the development of precur-
sors of long-term adverse cardiovascular health.
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growth. The cohort and study design have been described in 
detail previously11,12 and are available at the ALSPAC website 
(http://www.alspac.bris.ac.uk). The study website contains 
details of all data that is available through a fully searchable 
data dictionary (http://www.bris.ac.uk/alspac/researchers/
data-access/data-dictionary). Briefly, 14 541 pregnant women 
resident in a defined area of the South West of England, with 
an expected delivery date of April 1, 1991, to December 31, 
1992, were enrolled to the cohort. Of these, 13 988 live-
born children who were still alive 1 year later have been fol-
lowed up to date with regular questionnaires and clinical 
measures, providing behavioral, lifestyle, and biological data. 
Ethical approval for the study was obtained from the ALSPAC 
Ethics and Law Committee and the Local Research Ethics 
Committee. Written informed consent was obtained from 
the parent/guardian and, after the age of 16 years, children 
provided written assent.
Study Design
MR and RbG were used to test the hypothesis that BMI caus-
ally influences variations in multiple clinically relevant mea-
sures of cardiovascular structure and function in adolescence 
and early adulthood (Figure 1). First, we used a genetic risk 
score (GRS) comprising 97 BMI-associated single nucleotide 
polymorphisms (SNPs) shown to be robustly associated with 
BMI in the most recent genome-wide association study 
(GWAS),13 constructed using external weighting. This GRS 
was used as an instrumental variable (IV) within an MR frame-
work to investigate the causal effect of BMI on a range of 
vascular measures collected from those who attended the 
17-year clinic and underwent echocardiography (as part of 
the GRACE study).13 Estimates were compared with results 
obtained through observational analysis of the same associa-
tions. Second, we used data collected in a RbG framework to 
reproduce these findings and further explore their underlying 
mechanisms through the extensive phenotyping of a smaller 
group of independent individuals, recalled specifically on a 
genome-wide GRS distribution, constructed from results from 
the largest available GWAS of BMI conducted by Speliotes 
et al14 (at the initiation of recruitment to the RbG study) to 
explain the maximum possible proportion of variance in BMI 
(see Methods in the online-only Data Supplement).
Of those with full genetic data and consent (N=8350), 
individuals were invited to the RbG study based on the lower 
and upper ≈30% of the genome-wide GRS distribution.14 
Of those invited (N=2071), 419 individuals were successfully 
recalled at an average age of 21 years (see Methods and 
Figures I–III in the online-only Data Supplement).
Figure 1. Mendelian randomization and Recall-by-Genotype methodologies.  
Top left, In a Mendelian randomization (MR) analysis, the entire distribution of a genetic risk score (GRS, in pink) is used as an instrumental variable (IV) for body 
mass index (BMI; observations in blue and association with GRS represented with black line) to assess the causal nature of association between BMI and cardio-
vascular phenotypes (eg, left ventricular mass index [LVMI]). Bottom left, Comparison of observational multivariable regression (blue) and MR-derived estimates 
(pink), showing a positive association between BMI and LVMI using both methodologies. Top right, Instead of using the entire distribution of a GRS, the Recall-by-
Genotype (RbG) method creates genetically recalled samples from the tails of a GRS distribution (green), which are associated with BMI (observations in blue and 
association with GRS represented with black line). Bottom right, The RbG groups importantly show a difference in mean BMI between groups; however, there 
are no differences in confounding factors (equally sized “lifestyle factors” between groups). The RbG method therefore allows us to assess the change in detailed 
cardiovascular measures, obtained through precise techniques, between the recalled groups. Here, stroke volume (SV) is greater in those in the upper versus lower 
tail and systemic vascular resistance (SVR) is greater in the lower versus upper tail, both phenotypes of which were obtained through magnetic resonance imaging 
(MRI), which would not otherwise be feasible in large enough studies needed for MR methodology.
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We excluded data of all females who were pregnant or 
individuals who had diabetes mellitus at both the 17-year 
clinic (N=7 pregnancies and 15 diabetics) and the 21-year 
recall (N=1 pregnancy and 0 diabetics). After these exclu-
sions, 418 individuals were used in the 21-year RbG analyses 
and, of these, all had measured BMI, and the sample sizes of 
those with cardiovascular measures ranged between 386 to 
418 (Figure 2). In the independent sample of 7909 individuals 
that was used for MR analyses at age 17 years, 3404 had data 
on BMI and, of these, the sample sizes of those with cardio-
vascular measures ranged between 1420 to 3108 (Figure 2).
Measures of Adiposity at Ages 17 and 21 
Years
At both ages, height was measured to the nearest centimeter 
using a stadiometer (SECA 213, Birmingham, UK) and weight 
to the nearest 0.1 kg, unshod and in light clothing, using 
electronic weighing scales (Marsden M-110, Rotherham, 
UK). BMI was calculated as weight (kg) divided by height 
squared (m2).
Cardiovascular Phenotypes at Age 17 
Years
The following cardiovascular phenotypes were used in MR 
analyses to assess the causal role of BMI on cardiovascular 
health at age 17 years: blood pressure and heart rate, carotid-
femoral pulse wave velocity (PWV), carotid intima-media 
thickness (cIMT), and left ventricular mass index (LVMI). In 
addition, detailed phenotypes were measured using mag-
netic resonance imaging (MRI) at age 21 years (RbG study), 
including LVMI, stroke volume (SV), cardiac output (CO), sys-
temic vascular resistance, and total arterial compliance. See 
Methods in the online-only Data Supplement for details on 
phenotypic measurement.
Figure 2. Flow of samples used for Mendelian randomization and Recall-by-Genotype studies. 
The total number of individuals in ALSPAC with full genetic data and consent was 8350. Of these, 418 individuals were used in the Recall-by-Genotype (RbG) 
study, based on the lower and upper ≈30% of a continuous genome-wide genetic risk score (GRS) distribution for body mass index (BMI), constructed on the 
basis of results from a genome-wide association study (GWAS) of BMI.14 A total of 191 were within the lower tail and 227 were in the upper tail. The independent 
sample of 7909 individuals was used in MR analyses at age 17 years, which used a GRS comprising 97 SNPs (and constructed using external weighting) shown 
to be associated with BMI from a large-scale GWAS.13 The number of individuals with available data on the exposure (BMI) and on both BMI and cardiovascular 
outcomes are also presented (with numbers in the lower and upper tail of the RbG sample separated by “|”). ALSPAC indicates the Avon Longitudinal Study of 
Parents and Children; BMI, body mass index; cIMT, carotid intima-media thickness; CO, cardiac output; LVMI, left ventricular mass index; PWV, pulse wave velocity; 
SV, stroke volume; SVR, systemic vascular resistance; and TAC, total arterial compliance.
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Confounders
Because of potentially confounding effects, the following 
variables were added as covariates in observational analyses: 
maternal education and household occupation, plus current 
smoking status and the most recent records of physical activ-
ity and, where available, dietary intake. See Methods in the 
online-only Data Supplement for details on measures of these 
covariates.
Statistical Analyses
Preanalysis Transformations and Adjustments
As the distribution of residuals from the linear regression 
of BMI on carotid-femoral PWV was positively skewed, 
values of these variables were log-transformed for anal-
yses. For interpretation, differences and CIs were back-
transformed in all tables and figures and presented as 
the mean percentage difference in carotid-femoral PWV. 
Left ventricular mass measured at each age was indexed 
to height to the power of 2.7 (LVMI).15 To assess the 
impact of adiposity on central vascular measures over 
and above that caused by stature,16 systemic vascular 
resistance and total arterial compliance were adjusted 
for height using systemic vascular resistance×height1.83, 
total arterial compliance/height1.83, and both CO and 
SV measures were indexed to height by dividing CO by 
height1.83 and SV by height2.04.17 To assess the impact 
of missingness in our data, we compared the distribu-
tions of variables in those who had complete data (ie, 
no missing data in any variable) versus those included 
in our primary analyses. The magnitude of difference 
in all variables was negligible (Table I in the online-only 
Data Supplement); therefore, we present results based 
in the sample of individuals who had data on all neces-
sary variables for each analysis. A priori, we planned to 
draw conclusions based on effect estimates and their 
CIs, rather than statistical tests using an arbitrary P value 
cut-off.18,19 For example, given 2 effects with the same 
point estimate—one with narrow CIs, the other with 
wider CIs that may even include the null—we describe 
both as showing the same effect but note that one is 
more imprecisely estimated and should be treated with 
more caution until replicated in a larger sample. We 
did not take account of multiple testing given the high 
correlation between our outcome variables. The use of 
“positive” and “inverse” throughout the text refer to 
directional association rather than clinical implication. 
Stata 14 (Stata Corp) and R (https://cran.r-project.org/) 
were used for all analyses.
Multivariable Regression
Observational associations between BMI and each car-
diovascular phenotype at age 17 years were assessed 
using multivariable linear regression in 3 models: (1) un-
adjusted, (2) adjusted for age, sex, smoking status and 
dietary intake of the participant, household social class, 
and maternal education, and (3) additionally adjusted 
for physical activity (added as a separate model due to 
sample size). Associations of the confounders with BMI, 
each cardiovascular measure, and the weighted GRS at 
age 17 years were tested using linear regression.
Mendelian Randomization
The externally weighted GRS used as an IV for BMI in 
MR analyses was generated from the 97 SNPs shown 
to be reliably associated with BMI in the most recent 
GWAS conducted by the Genetic Investigation of AN-
thropometric Traits (GIANT) consortium.13 To generate 
the GRS, the dosage of each BMI-increasing allele at 
each locus in ALSPAC was weighted by the external ef-
fect size of the variant in the GWAS results.20 The doses 
were then added together and multiplied by the aver-
age external effect size of all the SNPs on BMI to reflect 
the number of average BMI-increasing alleles carried by 
each individual.
Two-stage least squares analysis was performed using 
the GRS as an IV for BMI at age 17 years to estimate β-
coefficients and standard errors from MR methodology 
(ivreg2 command in Stata). F statistics for the first-stage 
regression between the GRS and BMI were examined to 
check the instrument validity, satisfying the assumption 
that the GRS was sufficiently associated with the expo-
sure.21 The Durbin-Wu-Hausman test for endogeneity 
was used to compare multivariable regression and IV ef-
fect estimates (ivendog command in Stata).22
Recall-by-Genotype
Linear regression was used to assess the association of 
the RbG group allocation (upper versus lower ≈30% of 
the genome-wide GRS distribution, as described above) 
with BMI and each of the cardiovascular phenotypes 
measured at age 21 years. Each estimate therefore rep-
resents the mean difference in each variable with the 
corresponding mean difference in BMI between RbG 
groups (equivalent to a t test). The associations of the 
confounders with BMI, each cardiovascular measure at 
age 21 years, and the RbG group allocation were tested 
using linear and logistic regression, where appropriate.
Sensitivity Analyses
Both blood presssure (BP) and heart rate are correlated 
with other cardiovascular measures, namely carotid-fem-
oral PWV, cIMT, and LVMI.23–25 To assess the causal asso-
ciation between BMI and these cardiovascular measures, 
accounting for BP and heart rate, we took the residuals 
of the regression between each of these variables and 
both systolic BP (SBP) and heart rate, and repeated the 
MR and RbG main analyses using these residuals.
MR Analyses
Additionally, evidence suggests that some of the car-
diovascular phenotypes used in these analyses are not 
independent of height.15,26,27 To account for this and 
D
ow
nloaded from
 http://ahajournals.org by on November 16, 2018
Wade et al Causal Role of BMI on Cardiovascular Health
November 13, 2018 Circulation. 2018;138:2187–2201. DOI: 10.1161/CIRCULATIONAHA.117.0332782192
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
the inconsistent residual correlation between BMI and 
height throughout the lifecourse,28 we assessed the as-
sociation between the weighted GRS on height at age 
17 years and explored the impact of adjustment for 
height and height-squared on the association between 
the weighted GRS and BMI. We also adjusted both 
multivariable regression and MR analyses for height 
and height-squared and compared these to the main 
analyses.
The use of multiple alleles in MR analyses increases 
the potential for unbalanced pleiotropic effects (where 
the inclusion of invalid genetic instruments has an ag-
gregate effect in one particular direction).9,20,29 Where 
pleiotropy is perfectly balanced, an informative GRS is 
sufficient in an MR analysis, but this method is less able 
to cope with unbalanced pleiotropic effects. To investi-
gate the validity of the weighted GRS as an IV, the MR-
Egger approach was used to detect and accommodate 
violations of the MR assumptions.29 The intercept of the 
MR-Egger test can be interpreted as an estimate of the 
average pleiotropic effect across the genetic variants, 
with a nonzero intercept term indicating overall un-
balanced or directional pleiotropy. MR-Egger estimates 
were compared to those obtained from the inverse-
variance weighted and weighted median methods,29,30 
which provide estimates of the causal effect of BMI on 
cardiovascular phenotypes under varying assumptions 
of instrument validity. As in the main analyses, the es-
timates of the association between each SNP and BMI 
were obtained from an independent external source, 
as to not induce weak instrument bias in a 2-sample 
MR setting.31
Previous studies have suggested that the 97 SNPs 
used to construct the weighted GRS may have dif-
ferent properties in non-European populations.32 
Therefore, we performed a sensitivity analysis using a 
weighted GRS that was restricted to the genetic vari-
ants that were associated with BMI in the analysis of 
only people of European descent and excluded those 
that only reached genome-wide significance in 1 sex or 
stratum (n=77) in the GIANT consortium.13 Addition-
ally, a previous study in a large sample based in the UK 
suggested exclusion of 3 variants owing to pleiotropy 
(rs11030104, rs13107325, and rs3888190) and 3 SNPs 
that are not in Hardy-Weinberg equilibrium (P<1×10−6; 
rs17001654, rs2075650, and rs9925964).32 Therefore, 
as a sensitivity analysis, we excluded these additional 
SNPs, resulting in an IV consisting of 71 SNPs.
Additionally, to assess the validity of the genome-
wide GRS (used to recruit individuals to the RbG study, 
based on the Speliotes et al14 GWAS), MR analyses 
were conducted using the same genome-wide GRS as 
an IV for BMI, scaled to represent the same difference 
in mean BMI per unit increase as compared with the 
Locke et al13 GRS, comprising 97 SNPs, used in main 
MR analyses.
RESULTS
The MR cohort were 17.8 years old (SD = 0.4), consisted 
of 47.8% females, and had an average BMI of 22.7 kg/
m2 (SD = 4; Table 1). In the RbG study, individuals were 
21.5 years old (SD = 0.9) and had an average BMI of 24.5 
kg/m2 (SD = 5.7), and 65.8% were females (Table 2).
Multivariable Regression
Multivariable regression analyses provided evidence for 
positive associations of measured BMI with SBP, dia-
Table 1. Descriptive Statistics for ALSPAC 17-Year Clinic
Variable N
Mean (SD) or 
Percentage
Participant’s phenotypes
  Age, y 3493 17.79 (0.42)
  Sex, % female 7909 47.8
  BMI, kg/m2 3404 22.73 (3.99)
  SBP, mm Hg 3172 118.61 (10.95)
  DBP, mm Hg 3172 63.65 (6.56)
  PP, mm Hg 3172 54.96 (10.08)
  MAP, mm Hg 3172 81.97 (6.78)
  Mean cIMT, mm 3143 0.48 (0.04)
  Carotid-femoral PWV, m/s 2529 5.75 (0.69)
  LVMI, g/m2.7 1420 28.93 (6.11)
  Heart rate, bpm 3172 64.45 (9.80)
  Smoking status, % ever smoked 2844 51.6
  Physical activity at age 15 y   
  CPM, counts 1687 484.09 (180.99)
  MVPA, minutes 1687 23.73 (18.81)
  Dietary intake, kcal 7141 2260.24 (184.61)
Parental phenotypes
Highest household social class 6598  
  I 947 14.4
  II 2902 44.0
  III (nonmanual) 1651 25.0
  III (manual) 769 11.7
  IV 290 4.4
  V 39 0.6
Maternal education 6982  
  CSE 1156 16.6
  Vocational 635 9.1
  O-Level (age, 15-16 y) 2453 35.1
  A-Level (age, 17-18 y) 1700 24.4
  Degree 1038 14.9
BMI indicates body mass index; cIMT, carotid intima-media thickness; CPM, 
counts per minute; CSE, certificate of secondary education; DBP, diastolic blood 
pressure; LVMI, left ventricular mass indexed to height2.7; MAP, mean arterial 
pressure; MVPA, minutes spent in moderate-to-vigorous activity; PP, pulse 
pressure; PWV, pulse wave velocity; and SBP, systolic blood pressure.
D
ow
nloaded from
 http://ahajournals.org by on November 16, 2018
Wade et al Causal Role of BMI on Cardiovascular Health
Circulation. 2018;138:2187–2201. DOI: 10.1161/CIRCULATIONAHA.117.033278 November 13, 2018 2193
ORIGINAL RESEARCH 
ARTICLE
stolic BP (DBP), pulse pressure, mean arterial pressure 
(MAP), LVMI, and heart rate at age 17 years, as well 
as an inverse association with carotid-femoral PWV 
(Table 3).
Confounder Analyses
BMI and all the cardiovascular phenotypes were asso-
ciated with most of the confounding factors including 
highest household social class, maternal education, 
age, sex, smoking status, and dietary intake (Table 
II–X in the online-only Data Supplement). Unlike the 
direct measure of BMI and the cardiovascular pheno-
types, the GRS was not associated with a majority of 
confounders (Table XI in the online-only Data Supple-
ment). However, there was evidence for an associa-
tion between the GRS and dietary intake.
Mendelian Randomization
Each allele increase in the weighted GRS (compris-
ing 97 SNPs) was associated with a 0.12 kg/m2 (95% 
CI, 0.10–0.14; P=9.53×10-28) higher BMI, explaining 
3% of the variance (Figure I in the online-only Data 
Supplement). There was evidence for a positive effect 
of each kg/m2 higher BMI on SBP (difference: 0.79 
mm Hg; 95% CI, 0.30–1.28; P=0.002), DBP (differ-
ence: 0.29 mm Hg; 95% CI, 0.0002–0.59; P=0.05), 
pulse pressure (difference: 0.49 mm Hg; 95% CI, 
0.03–0.96; P=0.04), MAP (difference: 0.46 mm Hg; 
95% CI, 0.16–0.75; P=0.002), and LVMI (difference: 
1.07 g/m2.7; 95% CI, 0.62–1.52; P=3.87×10−06; Ta-
ble 4). F statistics for these analyses ranged from 36 
to 123, suggesting reasonable instrument strength. 
There was no strong evidence that the results from 
MR analyses were different from those from the mul-
tivariable regression analyses (all P values for com-
parison >0.12).
Recall-by-Genotype on BMI
Difference in mean BMI between RbG groups was 3.58 
kg/m2 (95% CI, 2.53–4.63; P=6.09×10−11; Table 5, Fig-
ure II in the online-only Data Supplement).
Confounder Analyses
Measures of both BMI and cardiovascular outcomes 
at age 21 years were associated with a majority of 
confounders, including highest household social class, 
maternal education, age, sex, smoking status, physi-
cal activity, and dietary intake (Tables XII-XXIV in the 
online-only Data Supplement). There was no strong 
evidence that the RbG group allocation was associ-
ated with confounders (Table XXV in the online-only 
Data Supplement).
Recall-by-Genotype and Cardiovascular 
Phenotypes
Of the cardiovascular measures that overlapped be-
tween the 2 methods (MR and RbG), the RbG groups 
were associated with higher SBP (difference in mean 
between upper versus lower RbG groups: 3.70 mm Hg; 
95% CI, 1.74–5.66; P=0.0002), DBP (difference: 2.25 
mm Hg; 95% CI, 0.98–3.52; P=0.001), MAP (differ-
ence: 2.73 mm Hg; 95% CI, 1.47–3.99; P=0.00003), 
and carotid-femoral PWV (difference: 3.28%; 95% CI, 
0.73–5.90%; P=0.01; Table 5).
Scaling the effect estimates to represent each kg/
m2 higher BMI, as in the MR analyses, these results are 
equivalent to a 1.03-mm Hg higher SBP, 0.63-mm Hg 
higher DBP, 0.76-mm Hg higher MAP, and 0.91% high-
er carotid-femoral PWV (Figure 3). There was therefore 
consistency between effect estimates on the overlap-
ping phenotypes at both ages (ie, each 1 kg/m2 higher 
BMI had a causal effect of similar magnitude on SBP, 
DBP, and MAP), while showing no association with 
heart rate or cIMT (Figure 3). However, there was evi-
dence for a positive causal effect of BMI on carotid-
femoral PWV in RbG analyses at age 21 years that was 
not evident in MR analyses at 17 years.
In addition to these cardiovascular measures, the RbG 
framework allowed the collection of more precise cardio-
vascular phenotypes. Of those specifically collected in the 
RbG arm of this work, there was evidence for a causal 
role of higher BMI on MRI-derived LVMI (difference in 
mean between upper versus lower RbG groups: 1.65 g/
m2.7; 95% CI, 0.83–2.47; P=0.0001), SV (difference: 1.49 
mL/m2.04; 95% CI, 0.62–2.35; P=0.001), and CO (differ-
ence: 0.11 L·min-1·m-1.83; 95% CI, 0.03–0.20; P=0.01), 
with no strong evidence of a difference in systemic vascu-
lar resistance or total arterial compliance (Table 5).
Sensitivity Analyses
After adjusting for SBP and heart rate, both MR and 
RbG results for the effect of BMI on cIMT, carotid-
femoral PWV, and LVMI were mostly consistent with 
the main analysis (Table XXVI in the online-only Data 
Supplement). The 1 exception was the positive effect 
of BMI on carotid-femoral PWV shown in RbG analysis, 
which attenuated to the null after adjustment for SBP 
and heart rate (difference: 1.56%; 95% CI, −0.71 to 
3.89%; P=0.18).
MR Analyses
The weighted GRS (comprising 97 SNPs) used in MR 
analyses was not associated with height or height-
squared at age 17 years. Adjusting for both height and 
height-squared made no difference to the association 
between the GRS and BMI at age 17 years (Table XXVII 
in the online-only Data Supplement), multivariable re-
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gression analyses (Table XXVIII in the online-only Data 
Supplement), or MR analyses (Table XXIX in the online-
only Data Supplement).
The MR-Egger test provided no strong evidence for 
unbalanced pleiotropic effects for any genetic variant 
included within the GRS on any cardiovascular outcome 
(all P values for the intercept ≥0.24; Table XXX in the 
online-only Data Supplement). The MR effect estimates 
from inverse-variance weighted, MR-Egger, and weight-
ed median analyses for the causal effect of BMI on the 
cardiovascular phenotypes were largely consistent with 
the main analyses, though the effect estimate of BMI 
on SBP did not agree for the weighted median analy-
ses in comparison with the main MR, inverse-variance 
weighted, and MR-Egger estimates, albeit with very 
wide CIs (Table XXX in the online-only Data Supplement 
and Figures III–VII in the online-only Data Supplement).
Both the IV containing 77 SNPs (Figure VIII in the 
online-only Data Supplement) and 71 SNPs (Figure IX in 
the online-only Data Supplement) were associated with 
BMI to a comparable extent as the GRS, comprising the 
full set of 97 SNPs based on the Locke et al13 GWAS 
(Table XXXI in the online-only Data Supplement) and 
produced similar results to the main analyses (Tables 
XXXII and XXXIII in the online-only Data Supplement, 
respectively). Similarly, when the genome-wide GRS 
(initially used to recall individuals to the RbG study and 
based on the Speliotes et al GWAS14) was implemented 
in MR analyses, the GRS was associated with a compa-
rable change in BMI (Table XXXI in the online-only Data 
Supplement, Figure X in the online-only Data Supple-
ment) and produced similar results to main MR analyses 
(Table XXXIV in the online-only Data Supplement).
DISCUSSION
In a large cohort of young adults, we used 2 comple-
mentary analyses (MR and RbG) to investigate the causal 
effect of higher BMI on measures of cardiovascular struc-
ture and function and compared these to adjusted mul-
tivariable regression results. Alongside MR analyses, RbG 
exploits the random assortment of alleles through meiot-
ic cell division at conception to inform genetically based 
recall and further allows for the collection of extremely 
precise cardiovascular phenotypes that would otherwise 
be impractical at a scale required to infer causality us-
ing MR analyses. Results suggest that higher BMI causes 
higher BP (SBP, DBP, PP, and MAP) and LVMI, the last sug-
gesting adverse cardiac structure, even in young adults.
Regarding the cardiovascular phenotypes that 
were used across MR, RbG, and multivariable regres-
sion analyses in the current study, our results are con-
sistent with previous observational studies in children 
and adults.33–35 For example, a recent study using MR 
methodology provided evidence that higher BMI and 
central adiposity (measured by BMI-adjusted waist-
hip ratio) increased the risk of coronary heart disease, 
type 2 diabetes mellitus, and echocardiographic mea-
sures indicative of left ventricular hypertrophy (such as 
the log Cornell product36). This highlights not only the 
Table 2. Descriptive Statistics for ALSPAC 21-Year RbG Group
Variable
RbG Group From 
the Lower Tail of 
the Genome-Wide 
GRS Distribution
RbG Group From 
the Upper Tail of 
the Genome-Wide 
GRS Distribution
N
Mean 
(SD) or 
Percentage N
Mean (SD) or 
Percentage
Participant’s phenotype
  Age, y 191 21.53 (0.93) 227 21.50 (0.95)
  Sex, % female 191 68.06 227 63.88
  BMI, kg/m2 191 22.58 (4.21) 227 26.16 (6.27)
  SBP, mm Hg 190 114.96 (9.25) 225 118.66 (10.80)
  DBP, mm Hg 190 66.01 (6.53) 225 68.26 (6.57)
  PP, mm Hg 190 48.95 (8.94) 225 50.40 (10.05)
  MAP, mm Hg 190 82.33 (6.26) 225 85.06 (6.72)
  Mean cIMT, mm 190 0.46 (0.04) 227 0.46 (0.04)
  Carotid-femoral PWV, m/s 184 5.49 (0.74) 220 5.66 (0.74)
  SVR, mm Hg·L-1·min-1 181 15.88 (3.06) 205 15.38 (2.97)
  TAC, mL/mm Hg 181 1.01 (0.22) 205 1.03 (0.23)
  LVMI, g/m2.7 181 20.55 (3.80) 205 22.20 (4.31)
  Heart rate, bpm 185 61.29 (9.18) 221 61.20 (9.66)
  SV, mL 181 87.05 (16.39) 205 92.02 (17.15)
  CO, L/min 181 5.53 (1.13) 205 5.84 (1.18)
  Smoking status, % ever 
smoked
191 16.75 226 17.70
  Weekly exercise, % 
never/rarely/<2 per week
143 41.96 156 35.26
Parental phenotypes
Highest household social 
class
164  206  
  I 42 25.61 49 23.79
  II 82 50.00 87 42.23
  III (nonmanual) 26 15.85 50 24.27
  III (manual) 10 6.10 17 8.25
  IV 4 2.44 3 1.46
Maternal education 169  211  
  CSE 10 5.92 21 9.95
  Vocational 9 5.33 19 9.00
  O-Level (age, 15-16 y) 50 29.59 59 27.96
  A-Level (age, 17-18 y) 51 30.18 69 32.70
  Degree 49 28.99 43 20.38
BMI indicates body mass index; cIMT, carotid intima-media thickness; 
CO, cardiac output; CSE, certificate of secondary education; DBP, diastolic 
blood pressure; GRS, genetic risk score; LVMI, left ventricular mass indexed 
to height2.7; MAP, mean arterial pressure; PP, pulse pressure; PWV, pulse wave 
velocity; RbG, Recall-by-Genotype; SBP, systolic blood pressure; SV, stroke 
volume; SVR, systemic vascular resistance; and TAC, total arterial compliance
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consistency of our current findings but also how our 
analyses build on the current literature with respect to 
the phenotypes measured and methods used.35 The 
similarity of findings across these methods, given dif-
ferent sources of bias between the MR and RbG on the 
one hand29 and multivariable regression on the other,9 
strongly supports causality in this instance. If further 
sustained through adulthood, these effects of higher 
BMI are likely to increase cardiovascular disease risk and 
cardiovascular disease–specific mortality in later life.37–40
Previous multivariable regression results from small-
er observational studies in children and adolescents 
have found higher BMI to be associated with faster ca-
rotid-femoral PWV and thicker cIMT.41–44 In contrast to 
this, our 3 methods gave results that did not support a 
causal effect for cIMT. This suggests that previous stud-
ies may have been influenced by residual confounding 
or bias, for which we have been better able to control 
here. This conclusion is also supported to some extent 
by analysis of the same variables at a younger age in 
Table 3. Multivariable Regression Associations Between BMI and Cardiovascular Phenotypes in ALSPAC 17-Year Clinic
Outcome (units)
Model 1 Model 2 Model 3
N
Difference in Mean 
Outcome per 1 kg/
m2 Higher BMI
(95% CI)* P Value N
Difference in 
Mean Outcome 
per 1 kg/m2 
Higher BMI
(95% CI)† P Value N
Difference in Mean 
Outcome per 1 kg/
m2 Higher BMI
(95% CI)‡ P Value
SBP, mm Hg 3108 0.86 (0.76, 0.95) 7.43×10−74 2389 0.84 (0.74, 0.94) 6.31×10−64 1033 0.83 (0.68, 0.98) 1.00×10−25
DBP, mm Hg 3108 0.52 (0.47, 0.58) 4.67×10−77 2389 0.49 (0.42, 0.56) 2.73×10−44 1033 0.47 (0.36, 0.58) 1.44×10−17
PP, mm Hg 3108 0.33 (0.25, 0.42) 1.98×10−13 2389 0.35 (0.26, 0.44) 6.08×10−15 1033 0.36 (0.22, 0.49) 3.97×10−07
MAP, mm Hg 3108 0.63 (0.58, 0.69) 1.13×10−109 2389 0.61 (0.54, 0.68) 2.89×10−68 1033 0.59 (0.48, 0.69) 5.64×10−27
Mean cIMT, mm 3079 0.0001
(–0.0003, 0.0005)
0.72 2368 −0.0001
(−0.001, 0.0004)
0.65 1028 0.0003
(−0.0005, 0.001)
0.48
Carotid-femoral 
PWV, %§
2495 –0.08
(–0.21, 0.05)
0.20 1957 −0.09
(−0.24, 0.05)
0.20 867 −0.26
(−0.48, −0.04)
0.02
LVMI, g/m2.7 1420 0.79 (0.72, 0.86) 7.66×10−108 1151 0.83 (0.75, 0.91) 2.02×10−99 569 0.95 (0.83, 1.07) 5.40×10−57
Heart rate, bpm 3108 0.21 (0.12, 0.29) 3.50×10−06 2389 0.20 (0.10, 0.31) 0.0001 1033 0.24 (0.08, 0.39) 0.003
BMI indicates body mass index; cIMT, carotid intima-media thickness; DBP, diastolic blood pressure; LVMI, left ventricular mass indexed to height2.7; MAP, mean 
arterial pressure; PP, pulse pressure; PWV, pulse wave velocity; and SBP, systolic blood pressure.
*Unadjusted.
†Adjusted for age, sex, smoking, and dietary intake of the participant and maternal education and household social class.
‡Additionally adjusted for physical activity of the participant.
§Percentage change in carotid-femoral PWV (m/s) per 1 kg/m2 higher in BMI. For analyses, carotid-femoral PWV was log-transformed for normalization of the 
residuals; therefore, differences and confidence intervals were back-transformed and represent the mean percentage difference in PWV.
Table 4. Mendelian Randomization Analyses of the Association Between BMI and Cardiovascular Phenotypes 
in ALSPAC 17-Year Clinic
Outcome (units) N
Difference in Mean 
Outcome per 1 kg/m2 
Higher BMI
(95% CI) P Value F Statistic
P Value for 
Difference*
SBP, mm Hg 3108 0.79 (0.30, 1.28) 0.002 115.76 0.78
DBP, mm Hg 3108 0.29 (0.0002, 0.59) 0.05 115.76 0.12
PP, mm Hg 3108 0.49 (0.03, 0.96) 0.04 115.76 0.49
MAP, mm Hg 3108 0.46 (0.16, 0.75) 0.002 115.76 0.24
Mean cIMT, mm 3079 0.002 (–0.001, 0.004) 0.14 122.97 0.15
Carotid-femoral PWV, %† 2495 –0.12 (–0.82, 0.59) 0.74 86.30 0.92
LVMI, g/m2.7 1420 1.07 (0.62, 1.52) 3.87×10−06 36.24 0.21
Heart rate, bpm 3108 –0.05 (–0.51, 0.41) 0.82 115.76 0.26
BMI indicates body mass index; cIMT, carotid intima-media thickness; DBP, diastolic blood pressure; LVMI, left ventricular 
mass indexed to height2.7; MR, Mendelian randomization; MAP, mean arterial pressure; PP, pulse pressure; PWV, pulse wave 
velocity; and SBP, systolic blood pressure.
*P value obtained from Durbin-Wu-Hausman test of heterogeneity between estimates obtained from unadjusted 
multivariable regression and MR analyses.
†Percentage change in carotid-femoral PWV (m/s) per 1 kg/m2 higher in BMI. For analyses, carotid-femoral PWV was log-
transformed for normalization of the residuals; therefore, differences and confidence intervals were back-transformed and 
represent the mean percentage difference in PWV.
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an observational context.33 With less consistent results 
across our approaches, higher BMI was associated 
with slower carotid-femoral PWV at age 17 years (ie, 
healthier PWV) in multivariable regression analysis and 
a faster carotid-femoral PWV (ie, worse PWV) in RbG 
analysis, with MR analysis showing a null association 
(Figure 3). Indeed, a previous study suggested that the 
relationship between BMI and PWV may be inverse in 
youth and becomes positive at older ages.45 This dis-
crepancy could indeed reflect a time-varying role of 
BMI on PWV but could also be a result of differential 
carotid-femoral PWV measurement techniques used 
between the 2 ages (a Vicorder device used at age 
17 years versus the SphygmoCor Vx device at age 21 
years) or chance.
As might be expected, higher BMI resulted in in-
creased CO in our RbG study and, although contrary 
to other observational studies at this age,46,47 this ap-
peared to be solely driven by SV, as neither our MR 
or RbG analyses suggested a causal effect of BMI on 
heart rate. It is possible that previously reported asso-
ciations between BMI and heart rate may be a result of 
unmeasured confounding. The BMI-mediated change 
in SV (and consequently CO) seen at age 21 years is 
therefore likely to at least partially account for the car-
diac hypertrophy and higher BP that we see in the data 
analyzed here.
A key strength of this work is the comparison of re-
sults from confounder-adjusted multivariable regression 
and MR, but also the ability to use the RbG framework 
to extend this analysis and use detailed cardiovascular 
phenotyping to explore causal associations. This is the 
first use of RbG for BP and cardiac structure, where we 
could compare results directly to multivariable regres-
sion and MR within the same general population. The 
consistency for shared phenotypes between results 
found from RbG (with 386–418 participants) to those 
from MR (with 1420–3108 participants) suggests that 
this approach is valid and statistically efficient. Further-
more, the RbG method allowed the collection of pre-
cise cardiovascular phenotypes that would otherwise 
not have been possible in sample sizes required for 
MR, while allowing causal inference. For example, we 
were able to explore the impact of BMI on MRI-derived 
SV and CO, measures that are prohibitively expensive 
to undertake and thus often inaccurately estimated in 
several thousands of participants. As opposed to other 
methods, the RbG study design used here afforded the 
possibility of collecting more precise MRI-derived car-
diovascular phenotypes, which are more likely to ac-
curately capture clinically relevant variation in cardio-
vascular health.
In contrast to these strengths, it is of course the case 
that both the MR and RbG analyses may be biased if 
IV analyses assumptions are violated.9 These require, 
first, that the genetic instruments need to be robustly 
related to the exposure (here, BMI). We used variants 
in both MR and RbG that have been shown to be ge-
nome-wide significant and replicated; the first-stage 
F-statistics, a measure of instrument strength, were 
high for all the MR analyses. Second, it is assumed that 
confounders of the observational BMI-cardiovascular 
outcome association are not related to the genetic in-
strument. There is empirical evidence that this is un-
likely to be the case and, for observed confounders, 
we demonstrated this in our analyses here.48 Third, 
it is assumed that there is no independent path from 
the genetic instrument to the outcomes other than 
through BMI, which may result from horizontal plei-
otropy. Although we aimed to make best use of all 
available data, our main analyses included the use of 
an aggregate GRS comprising all 97 SNPs associated 
with BMI, which may increase the possibility of hori-
zontal pleiotropy. Therefore, we used the best avail-
able methods for MR analyses with multiple IVs to test 
and, to some extent, account for pleiotropy. Across this 
range of sensitivity analyses (including the MR-Egger 
and weighted median approaches, as well as limiting 
the GRS to different subsets of genetic instruments), 
results were broadly similar to main analyses, lending 
more confidence to the causal estimates and direction 
of effect with higher BMI, suggesting that these were 
not largely driven by horizontal pleiotropy.
Table 5. Association Between RbG Groups and Cardiovascular 
Measures in ALSPAC 21-Year RbG Group
Outcome (units) N
Difference in Mean 
Outcome per 3.58 
kg/m2 Higher BMI
(95% CI)* P Value
Cardiovascular outcomes
  SBP, mm Hg 415 3.70 (1.74, 5.66) 0.0002
  DBP, mm Hg 415 2.25 (0.98, 3.52) 0.001
  PP, mm Hg 415 1.45 (–0.40, 3.30) 0.12
  MAP, mm Hg 415 2.73 (1.47, 3.99) 0.00003
  Mean cIMT, mm 417 0.001 (–0.01, 0.01) 0.82
  Carotid-femoral PWV, %† 404 3.28 (0.73, 5.90) 0.01
  SVR, mm Hg·L-1·min-1·m1.83 386 –1.03 (–2.49, 0.43) 0.17
  TAC, mL·mm Hg-1·m-1.83 386 0.01 (–0.01, 0.02) 0.37
  LVMI, g/m2.7 386 1.65 (0.83, 2.47) 0.0001
  Heart rate, bpm 406 –0.08 (–1.93, 1.77) 0.93
  SV, mL/m2.04 386 1.49 (0.62, 2.35) 0.001
  CO, L·min-1·m-1.83 386 0.11 (0.03, 0.19) 0.01
BMI indicates body mass index; cIMT, carotid intima-media thickness; CO, 
cardiac output; DBP, diastolic blood pressure; LVMI, left ventricular mass 
indexed to height2.7; MAP, mean arterial pressure; PP, pulse pressure; PWV, pulse 
wave velocity; RbG, Recall-by-Genotype; SBP, systolic blood pressure; SV, stroke 
volume; SVR, systemic vascular resistance; and TAC, total arterial compliance.
*Estimates generated by comparing 2 recalled groups.
†Percentage change in carotid-femoral PWV (m/s) comparing the 2 
recalled groups. For analyses, carotid-femoral PWV was log-transformed for 
normalization of the residuals; therefore, differences and confidence intervals 
were back-transformed and represent the mean percentage difference in PWV.D
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Although the RbG approach enabled sampling from 
the lower and upper ≈30% of a genome-wide GRS, 
which produced a difference of ≈3.5 kg/m2 in BMI, 
the genome-wide nature of the score could be con-
sidered less refined than the GRS used in MR analyses, 
comprising 97 SNPs shown to be robustly associated 
with BMI in a large meta-analyses of GWASs.13 Despite 
this, sensitivity analyses performed showed that the 
genome-wide GRS provided comparable results with 
MR analyses. Of those who participated in the RbG 
study, 386 individuals had full data on MRI-derived 
cardiovascular phenotypes. Although these measures 
were not present in the full sample (N=418), this is 
one of the largest collections of MRI-derived pheno-
types in individuals of this age that were collected in a 
manner that allowed causal inference of the effect of 
BMI on these phenotypes. Second, we used overlap-
ping phenotypes (such as blood pressure, pulse rate, 
and carotid-femoral PWV) in both the MR and RbG 
analyses primarily for comparison of causal estimates 
between the 2 ages. Thus, the current study provides 
both comparative and novel cardiovascular pheno-
types in the context of adiposity.
One complication in some of the sensitivity analy-
ses performed (specifically, adjusting for variables 
including BP, heart rate, and height in multivariable 
and MR analyses) is the potential for inducing collider 
or selection bias.49,50 However, because of the overall 
Figure 3. Comparison of estimates of all 
overlapping cardiovascular phenotypes 
available at both ages. 
Estimates represent the difference in mean 
outcome per 1 kg/m2 higher body mass index 
(BMI; graphs are separated by scale similarities) 
from multivariable regression (blue), Mendelian 
randomization (MR; pink), and Recall-by-
Genotype (RbG; green) methodologies. cIMT 
indicates carotid intima-media thickness; DBP, 
diastolic blood pressure; LVMI, left ventricular 
mass index; MAP, mean arterial pressure; PP, 
pulse pressure; PWV, pulse wave velocity; and 
SBP, systolic blood pressure.
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consistency in effect estimates generated from the 
various sensitivity analyses, this is unlikely to be the 
case. In addition, it is possible that some of the dif-
ferences in effect size of BMI on cardiovascular out-
comes (for example, carotid-femoral PWV) between 
ages may relate to either the difference in age at 
which the analyses were undertaken or phenotyping 
methods used at these ages. Given the small range of 
some of the cardiovascular outcomes (for example, 
cIMT) in these young individuals and the potentially 
small effect size of BMI, power to detect such small 
effect sizes in this context may be limited. Further, 
we adjusted for a range of potentially confounding 
factors in multivariable regression analyses, but even 
in such a comprehensive longitudinal cohort it can 
be difficult to accurately measure or observe (and 
therefore appropriately account for) all confounders. 
Indeed, this illustrates the need for better methods 
(such as MR and RbG used here) to assess the causal 
nature of the association between BMI and cardio-
vascular health, which aim to overcome such limita-
tions. Finally, in all analyses, we only included partici-
pants with complete data on all variables used in the 
specific model (ie, complete data on BMI, outcome 
and all confounders in multivariable analyses and on 
genetic instruments, BMI and outcome in Mendelian 
randomization). This assumes that missing data are 
missing at random. The similarity in characteristics 
between those with complete data and those with 
any missing data suggested that this assumption is 
unlikely to be violated.
With this innovative study design, using complemen-
tary multivariable regression, MR, and RbG analyses, to-
gether with a range of sensitivity analyses, results sug-
gest that higher BMI is likely to cause adverse levels of 
BP and LVMI, implying adverse cardiac structure, even 
in youth. RbG analyses also suggest that higher BMI 
results in increased CO, which appeared to be solely 
driven by SV, as neither MR nor RbG analyses suggested 
a causal effect of BMI on heart rate. These findings sup-
port efforts to reduce BMI from a young age, with the 
aim of attenuating the development of precursors of 
long-term adverse cardiovascular outcomes. Such ef-
forts may help prevent the development of additional 
cardiac and peripheral vascular damage not yet evident 
at this early stage of life.
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